MTN 020 (ASPIRE)
        Status:Completed
      
      
        Phase:III
      
      
        Principal Investigator(s):Jared Baeten, Thesla Palanee
      
      
        Objective:To assess the safety and effectiveness of a silicone elastomer vaginal matrix ring containing dapivirine worn for a month at a time.
Results released in February 2016:  found the dapivirine ring reduced the risk of HIV infection by 27% overall. Additional analysis released in July 2016 found that, among women who appeared to use the ring most regularly, HIV risk was cut by more than 50% across all analyses, and for those who benefitted the most, by 75% or more.
Last updated October 20, 2022
      
    
        Prevention Option(s):Microbicides
      
      
        Study Design:Controlled, Placebo, Randomized
      
                        Arms and Assigned Interventions
              
    Description4-week vaginal dapivirine (25 mg) ring
  
  
    Mode of DeliveryRing
  
  
    ARMsExperimental
  
          Official Code:
          
                          NCT01617096
                      
        
      
              
      
              
          Trial Sponsors:
          MTN, NIAID, NICHD, NIMH
        
          Start Date
            End Date
          July 24, 2012
            December 31, 2015
          
          Enrollment:3,540
        
        
          Age range:
          
            18 Years            ↔
                          45 Years                      
        
        
          Population:Cisgender Women